Evidence map›Paper›PMID 40806704›Full record

Trial reportInternational journal of molecular sciences2025

Mechanistic Insights and Real-World Evidence of Autologous Protein Solution (APS) in Clinical Use.

Jennifer Woodell-May, Kathleen Steckbeck, William King, Katie Miller, Bo Han, Vikas Vedi, Elizaveta Kon

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jennifer Woodell-MayZimmer Biomet, 56 E Bell Drive, Warsaw, IN 46580, USA.
Kathleen SteckbeckZimmer Biomet, 56 E Bell Drive, Warsaw, IN 46580, USA.
William KingZimmer Biomet, 56 E Bell Drive, Warsaw, IN 46580, USA.
Katie MillerZimmer Biomet, 56 E Bell Drive, Warsaw, IN 46580, USA.
Bo HanKeck School of Medicine of USC, University of Southern California, 1333 San Pablo St., Los Angeles, CA 90033, USA.ORCID 0000-0003-1458-4265
Vikas VediBishops Wood Hospital, Rickmansworth Rd, Northwood HA6 2JW, UK.
Elizaveta KonIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.ORCID 0000-0003-0649-2336

Funding

Zimmer Biomet (United States) N/A
6 · The paper itself

Abstract

Autologous therapies are currently being studied to determine if they can modulate the course of knee osteoarthritis symptoms and/or disease progression. One potential therapeutic target is the polarization of pro-inflammatory M1 macrophages to pro-healing M2 macrophages. The autologous therapy, Autologous Protein Solution (APS), was incubated with donor-matched human peripheral-derived macrophages for 10 days. M1 pro-inflammatory macrophages were determined by the percentage of CD80+ and M2 pro-healing macrophages were determined by CD68+ and CD163+ by epifluorescent microscopy. To determine clinical effectiveness, an APS-specific minimal clinically important improvement (MCII) using an anchor-based method was calculated in a randomized controlled trial of APS (

Indexed as

MacrophagesOsteoarthritis, KneeAgedFemaleHumansMaleMiddle AgedTreatment OutcomeAutologous protein solution (APS)M1 M2 macrophagesminimally clinically important improvement (MCII)Osteoarthritis (OA)

Identifiers

PMID40806704
PMCPMC12347645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.